Quoin Pharmaceuticals

QNRXPhase 3

Ashburn, United StatesFounded 2018quoinpharma.com

Quoin Pharmaceuticals is a NASDAQ-listed company (QNRX) dedicated to addressing critical unmet medical needs in rare and orphan diseases, with a mission to 'bring hope where there is currently none.' Its innovative pipeline, centered on proprietary topical rapamycin formulations, targets severe dermatological and vascular conditions like Netherton Syndrome, Peeling Skin Syndrome, and Microcystic Lymphatic Malformations. The company has secured key regulatory designations (Orphan Drug, Rare Pediatric Disease) in the US and EU, is executing multiple clinical trials, and has built a global commercial network ahead of potential product launches.

Market Cap

$12.8M

Founded

2018

Focus

Cell & Gene Therapy

AI Company Overview

Technology Platform

Proprietary topical drug delivery technologies, specifically for rapamycin (sirolimus), designed to achieve target drug loadings and treat localized rare disease indications.

Pipeline Snapshot

3 drugs in pipeline, 3 in Phase 3

Drug	Indication	Stage
QRX003-2% Lotion + QRX003-4% Lotion QAM + Vehicle + QRX003-4% Lotion BID	Netherton Syndrome	Phase 2/3
QRX003, 4% Lotion	Netherton Syndrome	Phase 2/3
QRX003, 4% Lotion	Netherton Syndrome	Phase 2/3

Funding History

Total raised: $25M

IPO$10MUndisclosedDec 15, 2021

Series A$15MUndisclosedMay 15, 2019

Opportunities

Major opportunity lies in being first-to-market for Netherton Syndrome, a condition with no approved therapies.

Success there validates the platform for expansion into other rare dermatological indications like Peeling Skin Syndrome and Ichthyosis.

The global commercial network spanning 61 countries provides a rapid pathway to worldwide revenue generation post-approval.

Risk Factors

Extreme dependency on the success of a single lead candidate (QRX003) in ongoing pivotal trials.

As a pre-revenue micro-cap company, significant financing risk and potential shareholder dilution exist.

Execution risk in building internal commercial infrastructure and managing a complex network of ex-US partners.

Competitive Landscape

Direct competition in Netherton Syndrome is minimal due to the lack of approved therapies, providing a first-mover advantage. Broader competition exists in the topical rapamycin space for other indications. Quoin differentiates through its specific formulation technology, orphan drug designations, and focused rare disease strategy with an established global commercial footprint.